Form 8-K - Current report:
SEC Accession No. 0001193125-25-111633
Filing Date
2025-05-02
Accepted
2025-05-02 16:14:40
Documents
13
Period of Report
2025-05-01
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 8-K d830663d8k.htm   iXBRL 8-K 25329
  Complete submission text file 0001193125-25-111633.txt   147093

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ovid-20250501.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20250501_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20250501_pre.xml EX-101.PRE 11259
15 EXTRACTED XBRL INSTANCE DOCUMENT d830663d8k_htm.xml XML 3632
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 25908701
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)